X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs CIPLA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES CIPLA DIVIS LABORATORIES/
CIPLA
 
P/E (TTM) x 18.1 44.1 41.2% View Chart
P/BV x 3.9 3.6 108.1% View Chart
Dividend Yield % 1.6 0.4 446.1%  

Financials

 DIVIS LABORATORIES   CIPLA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
CIPLA
Mar-17
DIVIS LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,484622 399.4%   
Low Rs918458 200.3%   
Sales per share (Unadj.) Rs142.3181.9 78.2%  
Earnings per share (Unadj.) Rs41.912.9 325.4%  
Cash flow per share (Unadj.) Rs46.329.3 158.1%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %0.60.4 158.8%  
Book value per share (Unadj.) Rs161.5155.7 103.7%  
Shares outstanding (eoy) m265.47804.51 33.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x12.03.0 402.6%   
Avg P/E ratio x40.642.0 96.8%  
P/CF ratio (eoy) x36.718.4 199.2%  
Price / Book Value ratio x10.53.5 303.6%  
Dividend payout %23.915.5 153.6%   
Avg Mkt Cap Rs m451,525434,516 103.9%   
No. of employees `0003.723.0 16.1%   
Total wages/salary Rs m3,64926,338 13.9%   
Avg. sales/employee Rs Th10,184.46,349.1 160.4%   
Avg. wages/employee Rs Th984.11,143.0 86.1%   
Avg. net profit/employee Rs Th2,998.5449.3 667.3%   
INCOME DATA
Net Sales Rs m37,764146,302 25.8%  
Other income Rs m8482,287 37.1%   
Total revenues Rs m38,612148,589 26.0%   
Gross profit Rs m14,13824,758 57.1%  
Depreciation Rs m1,18213,229 8.9%   
Interest Rs m231,594 1.5%   
Profit before tax Rs m13,78112,222 112.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,6621,798 148.1%   
Profit after tax Rs m11,11910,354 107.4%  
Gross profit margin %37.416.9 221.2%  
Effective tax rate %19.314.7 131.4%   
Net profit margin %29.47.1 416.0%  
BALANCE SHEET DATA
Current assets Rs m30,94787,370 35.4%   
Current liabilities Rs m5,19533,081 15.7%   
Net working cap to sales %68.237.1 183.8%  
Current ratio x6.02.6 225.5%  
Inventory Days Days11787 134.3%  
Debtors Days Days8562 136.7%  
Net fixed assets Rs m17,027111,567 15.3%   
Share capital Rs m5311,609 33.0%   
"Free" reserves Rs m42,341123,645 34.2%   
Net worth Rs m42,877125,254 34.2%   
Long term debt Rs m536,454 0.0%   
Total assets Rs m49,684209,532 23.7%  
Interest coverage x595.08.7 6,864.2%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.80.7 108.9%   
Return on assets %22.45.7 393.3%  
Return on equity %25.98.3 313.7%  
Return on capital %32.28.5 378.7%  
Exports to sales %85.334.2 249.2%   
Imports to sales %22.98.3 274.8%   
Exports (fob) Rs m32,19850,050 64.3%   
Imports (cif) Rs m8,65412,203 70.9%   
Fx inflow Rs m32,27051,066 63.2%   
Fx outflow Rs m8,77517,678 49.6%   
Net fx Rs m23,49633,388 70.4%   
CASH FLOW
From Operations Rs m10,37923,824 43.6%  
From Investments Rs m-4,135-13,127 31.5%  
From Financial Activity Rs m-6,241-13,239 47.1%  
Net Cashflow Rs m3-2,478 -0.1%  

Share Holding

Indian Promoters % 52.0 16.0 325.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 11.8 12.2 96.7%  
FIIs % 19.0 23.7 80.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.2 26.2 65.6%  
Shareholders   31,796 161,166 19.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFE  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS